Serotonin-Norepinephrine Reuptake Inhibitors, Mirtazapine, and Bupropion

Norepinephrine released in descending spinal pathways suppresses nociceptive transmission at the dorsal horn — a pain-modulating mechanism that pure serotonin reuptake inhibitors do not reliably activate at therapeutic doses. By blocking the norepinephrine reuptake transporter, serotonin-norepinephrine reuptake inhibitors augment this descending inhibitory signal, producing analgesic effects that underlie their approved indications in diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain. This same noradrenergic activity also accounts for cardiovascular effects — blood pressure elevation and heart rate increase — that require monitoring not needed with selective serotonin reuptake inhibitors.

Venlafaxine is the most widely prescribed serotonin-norepinephrine reuptake inhibitor and has a pharmacodynamically distinctive feature: its norepinephrine reuptake blockade is dose-dependent. At low doses (75 mg per day or below), venlafaxine behaves pharmacologically like a selective serotonin reuptake inhibitor — the serotonin transporter is its primary target and norepinephrine transporter inhibition is minimal. At higher doses (150 mg per day and above), meaningful norepinephrine transporter inhibition emerges, and at 225 mg per day the dual mechanism is fully expressed. This dose-dependence means that a patient who fails to respond at low doses has not yet had an adequate trial of the drug's dual mechanism — escalation is pharmacologically rational before declaring failure.

Venlafaxine is metabolized to desvenlafaxine (O-desmethylvenlafaxine), which is approved as a separate antidepressant. The immediate-release formulation has a short half-life and must be taken twice or three times daily; the extended-release formulation permits once-daily dosing and significantly reduces the risk of discontinuation symptoms from missed doses, though this risk remains higher than with selective serotonin reuptake inhibitors. Venlafaxine extended-release is approved for major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder.

Duloxetine achieves meaningful inhibition of both the serotonin and norepinephrine transporters across its full therapeutic dose range — no dose-dependent duality as seen with venlafaxine. It has the broadest Food and Drug Administration approval of the class: major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain. This pain portfolio makes duloxetine the preferred serotonin-norepinephrine reuptake inhibitor when analgesia is a co-primary treatment goal.

Duloxetine is a moderate inhibitor of cytochrome P450 2D6, which can raise plasma concentrations of tricyclic antidepressants and some antipsychotics — monitor when adding to complex regimens. It carries a hepatotoxicity risk, rare but real, and should be avoided in patients with substantial alcohol use or pre-existing liver disease. Narrow-angle glaucoma is a contraindication due to mydriatic effects from noradrenergic activity.

Desvenlafaxine, the active metabolite of venlafaxine developed as a standalone agent, is approved for major depressive disorder at a fixed dose of 50 mg per day. It has minimal cytochrome P450 inhibition and avoids the metabolic variability of the parent compound. Levomilnacipran has the strongest norepinephrine transporter selectivity of the class — it inhibits the norepinephrine transporter more potently than the serotonin transporter, giving it a more noradrenergic profile than duloxetine or venlafaxine. It is approved for major depressive disorder only and has low cytochrome P450 drug interaction potential, making it a cleaner pharmacokinetic choice when polypharmacy is a concern. A distinctive adverse effect of levomilnacipran is urinary hesitancy, more prominent than with other agents in the class, due to strong noradrenergic stimulation of the internal urethral sphincter.

Presynaptic alpha-2 adrenergic autoreceptors on noradrenergic neurons normally act as a negative feedback brake — when norepinephrine activates them, they suppress further norepinephrine release. Mirtazapine blocks these receptors, removing the brake and allowing greater norepinephrine release with each neuronal firing. The same alpha-2 receptors located on serotonergic terminals also suppress serotonin release when activated by norepinephrine; mirtazapine blocks these as well, disinhibiting serotonin release simultaneously. The result is enhanced output of both norepinephrine and serotonin through a presynaptic mechanism.

At postsynaptic serotonin receptors, mirtazapine blocks the serotonin-2A, serotonin-2C, and serotonin-3 subtypes. Serotonin-3 blockade produces a pronounced antiemetic effect — patients on mirtazapine rarely experience the nausea that limits tolerability with selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors. Serotonin-2C blockade increases appetite and promotes weight gain, which is therapeutically useful in patients with depression-related anorexia and weight loss but is an adverse effect in others. Mirtazapine is also a potent histamine H1 antagonist, which produces marked sedation — most pronounced at lower doses and the basis for its common use at bedtime.

Mirtazapine has a counterintuitive dose-sedation relationship: it is more sedating at lower doses (15 mg) than at higher doses (30 to 45 mg). This occurs because histamine H1 antagonism, which drives sedation, is maximal across the full dose range, while the alpha-2 blockade-mediated increase in norepinephrine output at higher doses produces noradrenergic activation that partially counteracts histaminergic sedation. Clinically, patients troubled by daytime sedation at 15 mg may actually tolerate 30 mg better — the opposite of the usual expectation.

Mirtazapine's receptor profile defines when it is preferred. It is well-suited for patients with depression plus significant insomnia (sedation is an asset given at bedtime), patients with poor appetite and weight loss (serotonin-2C blockade stimulates appetite), and patients who cannot tolerate the nausea of serotonin transporter inhibitors (serotonin-3 blockade prevents nausea). Because it does not increase serotonin tone via the serotonin-2A pathway, mirtazapine does not cause the sexual dysfunction that affects roughly a third of patients on selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors. It also has no clinically significant cytochrome P450 inhibition, making it one of the cleaner choices for drug interaction burden.

Weight gain is mirtazapine's most clinically limiting adverse effect — driven by serotonin-2C and H1 blockade, it is among the most weight-promoting antidepressants available. This should be discussed explicitly before initiation. Mirtazapine is frequently combined with a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor as an augmentation strategy, exploiting complementary mechanisms: reuptake inhibition plus receptor disinhibition.